Bone Health in Duchenne muscular dystrophy

Your views matter about bone health. There’s still time to take part in an important survey to improve bone health in Duchenne. The links below will take you to the survey (Closes end April 2018).

Takes about 10 minutes and you can take part if you are over 14 years old and living with Duchenne or if you are a parent or main carer of a child (any age) with Duchenne. The results will be discussed at a ENMC (European Neuro Muscular Centre) workshop in June.

The survey is part of the ScOT-DMD Bone Health

More information

If you have any queries please contact Angela Stringer on 020 7250 8240 or [email protected]

Latest

Duchenne Parent Project International Conference

This weekend our Director of Research, Neil Bennett, and our CEO, Shelley Simmonds, are in Rome attending the Duchenne Parent Project International Conference.
Golf Club raise £3,050 in villa raffle

Last weekend, our wonderful supporters Stoke By Nayland Golf Club held their much anticipated raffle draw. The prize was a week in a luxury villa in Cyprus, with space for 8 people to enjoy the pool, sun and gorgeous relaxing surroundings.
Solid Biosciences announce preliminary trial results

Solid Biosciences have announced preliminary data from their IGNITE-DMD clinical trial that is testing the safety and effectiveness of an adeno-associated virus (AAV) gene therapy.
Our vision

Action Duchenne has a clear vision: a world where lives are no longer limited by Duchenne muscular dystrophy.

Duchenne Parent Project International Conference

This weekend our Director of Research, Neil Bennett, and our CEO, Shelley Simmonds, are in Rome attending the Duchenne Parent Project International Conference.
Golf Club raise £3,050 in villa raffle

Last weekend, our wonderful supporters Stoke By Nayland Golf Club held their much anticipated raffle draw. The prize was a week in a luxury villa in Cyprus, with space for 8 people to enjoy the pool, sun and gorgeous relaxing surroundings.
Solid Biosciences announce preliminary trial results

Solid Biosciences have announced preliminary data from their IGNITE-DMD clinical trial that is testing the safety and effectiveness of an adeno-associated virus (AAV) gene therapy.
Family urge PTC to fight for Translarna approval

Cormac Fegan, age 8, and his family were invited to give a Q&A session to mark the start of the second day of the event to over 150 attendees from all areas of the company covering all geographic areas.
Call to action - Powerchair Football in Scotland

Please join the Cross Party Debate discussing Powerchair football in Scotland on Wednesday the 6th of February 2019 at 5:15pm in Scottish Parliament.
HOPE-2 update from Capricor Therapeutics

Capricor Therapeutics update on it’s HOPE-2 clinical trial of CAP-1002, a potential treatment for Duchenne muscular dystrophy.
What your money buys

If you're supporting one of our many Duchenne research projects, here's an idea of where your money goes, and how every penny counts.
Edasalonexent update from catabasis

Catabasis has announced that the phase 3 trial of edasalonexent is now recruiting at 9 centres across the USA and that regulatory approval for the trial to start in Europe has been received.
Sarepta completes accelerated approval application for golodirsen

Sarepta Therapeutics has completed the submission of a request for accelerated approval for golodirsen in the USA
UNITE-DMD project update - Year 1

Update on the progress of the UNITE-DMD programme that we fund jointly with MDUK and AFM-Telefon.

Donate to Action Duchenne

Help power our work and join us in making history
Our team
Conference registration

Register for the Action Duchenne International Conference 2018
GDPR updating personal information

Please let us know if the personal information that we hold about you needs to be corrected or updated.
What are the signs and symptoms of Duchenne?
How are drugs licensed and approved in the UK?
Our vision

Action Duchenne has a clear vision: a world where lives are no longer limited by Duchenne muscular dystrophy.
Revised Standards of Care for Duchenne muscular dystrophy

Action Duchenne originally co-funded the translation of the original standard of care guidelines, into the widely used family guide and continues to be at the forefront of these developments.
Adults living with Duchenne muscular dystrophy

We have always advocated for the best standards of care for people living with Duchenne. Early on, we identified the importance of helping young people living with Duchenne to equip themselves with the skills and power to achieve the best life possible.
Guides and information

As well as funding research into potential treatments and one day a cure, we also produce a range of resources to benefit the global Duchenne community.

Brighton Marathon 14 April 2019

Join the Action Duchenne Brighton Marathon Team today and take in one of Britain's most cosmopolitan cities. Read more

Bone Health in Duchenne muscular dystrophy

Your views matter about bone health. There’s still time to take part in an important survey to improve bone health in Duchenne. The links below will take you to the survey (Closes end April 2018).

Parent/guardian/primary carer survey

Adolescent with Duchenne survey (aged 14 years and older)

Takes about 10 minutes and you can take part if you are over 14 years old and living with Duchenne or if you are a parent or main carer of a child (any age) with Duchenne. The results will be discussed at a ENMC (European Neuro Muscular Centre) workshop in June.

The survey is part of the ScOT-DMD Bone Health

More information

If you have any queries please contact Angela Stringer on 020 7250 8240 or [email protected]

Further reading

Action Duchenne funded ScOT-DMD study

Revised Standard of Care for Duchenne

ScOT-DMD research study update